Total
0
Shares
What do investors stand to gain from Australia’s clinical trial landscape?
Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) has secured a patent from the European regulator covering two of its synthetic anti-infective formulations
  • This is the second time Recce has been granted a patent in the Patent Family 3 group after a patent was previously granted by Japan's regulator
  • The new patent will cover marketing and manufacturing activities associated with the company's Recce 327 and Recce 529 drug candidates until February 2037
  • These drugs aim to stop the rapid spread of bacteria and viruses, respectively
  • The new E.U. patent also covers Recces's use of the candidates on viruses like COVID-19, HIV and Ross River Virus
  • Shares in RCE ended the day at 96.5 cents per share

Recce Pharmaceuticals (RCE) has secured a patent from the European regulator covering two of its synthetic anti-infective formulations.

The new patent will cover marketing and manufacturing activities associated with the company's Recce 327 and Recce 529 drug candidates until February 2037.

These drugs aim to stop the rapid spread of bacteria and viruses, respectively, and both are at different stages of development.

Additionally, the new E.U. patent allows for the use of these drugs on viruses like COVID-19, HIV and Ross River Virus.

It also protects how R327 or R529 is administered, be it orally, via injection, inhalation or transdermal dose application.

This is the second time the healthcare stock has been granted a patent from the Patent Family 3 group. Japan's regulator has also granted Recce a similar patent from this patent family, with further international applications pending.

Commenting on the patent, Recce Chief Executive Officer James Graham said the E.U. was a key market for the company's drugs.

"Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us," he said.

"Our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens," James concluded.

Shares in Recce Pharmaceuticals ended Tuesday's session trading at 96.5 cents per share.

RCE by the numbers
More From The Market Herald
Oventus Medical (ASX:OVN) - Chairman, Sue MacLeman (centre left) - The Market Herald

" Oventus Medical (ASX:OVN) eyes $5M placement to strengthen balance sheet

Sleep apnoea specialist Oventus Medical (OVN) has received firm commitments to undertake a $5 million placement.
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) commences prostate cancer clinical trial

Telix Pharmaceuticals (TLX) has been given the green light to commence a phase three clinical trial of its targeted therapy candidate TLX591 in
Bod Australia (ASX:BDA) - CEO, Jo Patterson - The Market Herald

" Bod Australia (ASX:BDA) records highest ever month of MediCabilis sales

Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April.
Prescient Therapeutics (PTX) -CEO & Managing Director, Steven Yatomi - The Market Herald

" Prescient Therapeutics (ASX:PTX) signs new research agreement with Peter MacCallum Cancer Centre

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs.